The associate professor at Fred Hutch Cancer Center discussed data presented at the EHA 2022 Congress.
"We have not seen any grade 3 or 4 CRS and we haven't seen neurotoxicity at any grade for follicular lymphoma... It’s important to keep in mind, when we discuss different options with patients, especially in low grade lymphomas, the threshold for accepting toxicity may be different given the competitive landscape and different treatments that we have.”
MB-106, Mustang Bio’s CD20-targeted chimeric antigen receptor (CAR) T-cell therapy, demonstrated efficacy in the follicular lymphoma (FL) cohort of a phase 1/2 trial (NCT03277729). Findings from the cohort were presented at the European Hematology Association (EHA) 2022 Congress, June 9-12, held both virtually and in Vienna, Austria, by Mazyar Shadman, MD, MPH, associate professor, clinical research division, Fred Hutchinson Cancer Center, where the trial was conducted.
The trial has treated 18 patients in the FL cohort. All patients, except for the first of each dose cohort, were infused in the outpatient setting. Overall response rate (ORR) was 94% (n = 17) and complete response (CR) rate was 78% (n = 14). Three patients (17%) had a partial response and 1 (5%) experienced disease progression. No cases of grade 3 or above cytokine release syndrome were observed and there was no neurotoxicity observed.
CGTLive spoke with Shadman to learn more about the findings from the FL cohort. He discussed the positive efficacy and safety data and the next, multicenter trial of MB-106 that is now enrolling.